EE105 Triamcinolone Acetonide Injectable Suspension, for Suprachoroidal Use, for the Treatment of Macular Edema Associated with Uveitis in the United States: A Budget Impact Analysis.

MLA

Bhattacharyya, S., et al. “EE105 Triamcinolone Acetonide Injectable Suspension, for Suprachoroidal Use, for the Treatment of Macular Edema Associated with Uveitis in the United States: A Budget Impact Analysis.” Value in Health, vol. 25, no. 7, July 2022, p. S355. EBSCOhost, https://doi.org/10.1016/j.jval.2022.04.358.

APA

Bhattacharyya, S., Hariprasad, S., Albini, T., John, D., Dutta, S., Cohen, B., Dashputre, A., Harrison, D., & Joseph, G. (2022). EE105 Triamcinolone Acetonide Injectable Suspension, for Suprachoroidal Use, for the Treatment of Macular Edema Associated with Uveitis in the United States: A Budget Impact Analysis. Value in Health, 25(7), S355. https://doi.org/10.1016/j.jval.2022.04.358

Chicago

Bhattacharyya, S, Sm Hariprasad, Ta Albini, D John, Sk Dutta, B Cohen, Aa Dashputre, D Harrison, and G Joseph. 2022. “EE105 Triamcinolone Acetonide Injectable Suspension, for Suprachoroidal Use, for the Treatment of Macular Edema Associated with Uveitis in the United States: A Budget Impact Analysis.” Value in Health 25 (7): S355. doi:10.1016/j.jval.2022.04.358.